Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 30, 2026
Foghorn Therapeutics Inc. (FHTX)
A forensic read on Foghorn Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-10.3
Altman Z-score
Clean
Earnings quality
3
Forensic signals
$285M
Market cap
Foghorn Therapeutics Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -10.3, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-119%Return on invested capital.Return on invested capital is -119% and slipping from -31% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+17.1%/yrShare-count dilution.Diluted share count changed +51% over the last 3 years to FY2025 (+17.1%/yr). The count is GROWING — existing holders are being diluted. That's ~17.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~51%.
34% of revStock-based comp load.Stock-based compensation ran 34% of revenue in FY2025 — about $0.17 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-240.3%
Free Cash Flow$-86.1M
Latest Revenue$30.9M
Revenue Growth YoY+36.8%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Foghorn Therapeutics Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about FHTX's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown